- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
- Interventions
- Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 365 Days to 31 Years
- Enrollment
- 6,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 201
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 1,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
- Conditions
- Retraction of Colostomy
- Interventions
- IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Orlando, Florida • Tampa, Florida
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Bortezomib, Doxorubicin hydrochloride (HCl), PEG-Asparaginase, Vincristine sulfate, Dexamethasone, Cytarabine, Methotrexate
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Human Immunodeficiency Virus
- Interventions
- tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy
- Drug · Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Dorothy Sipkins, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- filgrastim, cisplatin, cyclophosphamide, lomustine, mesna, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 22 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2011
- U.S. locations
- 36
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 29 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, vinblastine sulfate, phosphorus P32, radiation therapy
- Drug · Radiation
- Lead sponsor
- Center for Molecular Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Garden City, New York
- Conditions
- Lymphoma
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2015
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
- Conditions
- Neurofibromatosis 1
- Interventions
- Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin)
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Lymphoma
- Interventions
- filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone, Atazanavir and Dexamethasone
- Drug · Combination Product
- Lead sponsor
- Biomed Industries, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 27 more
- Conditions
- Anesthesia, Pain
- Interventions
- Ketorolac Tromethamine, Hydromorphone, Ketamine, Oxycodone, Morphine, Fentanyl (IV)
- Drug
- Lead sponsor
- Chi Dang Hornik
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Stanford, California • Aurora, Colorado • Wilmington, Delaware + 7 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Lymphoma
- Interventions
- doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
- Conditions
- Postoperative Pain, Inflammation, Osteoarthritis
- Interventions
- Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
- Drug
- Lead sponsor
- Thomas L Bradbury
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Tucker, Georgia
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Miami, Florida + 12 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 18
- States / cities
- La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more
- Conditions
- Hiv
- Interventions
- V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Solid Tumor, Hematological Malignancies
- Interventions
- Belinostat, Atazanavir
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- B-Cell Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir, Lamivudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Asthma
- Interventions
- Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate
- Drug · Other
- Lead sponsor
- Global United Pharmaceutical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Augusta, Georgia